Moon Fenton
Hematology & Oncology · Beaver, PANPI 1891995288
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.0% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,490 and has fallen 90.7% since, to $138 in 2025.
Across 141 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$280
- E.r. Squibb & Sons, L.L.C.$262
- Johnson & Johnson$245
- Puma Biotechnology, Inc.$153
- Bristol Myers Squibb$124
- Amgen$118
- plus $1K from 31 others
Across 71 payments — averaging $1359.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$83K
- Astrazeneca UK Limited$7K
- E.r. Squibb & Sons, L.L.C.$4K
- Merck$2K
What the payments were for
- Food & beverage$2,23290%
- Education$24710%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 13 | $280 |
| E.r. Squibb & Sons, L.L.C. | 6 | $262 |
| Johnson & Johnson(2 entities) | 16 | $245 |
| Puma Biotechnology, Inc. | 10 | $153 |
| Bristol Myers Squibb | 7 | $124 |
| Amgen | 7 | $118 |
| Eisai Inc. | 8 | $117 |
| AbbVie | 2 | $100 |
| Merck | 6 | $91 |
| Lilly USA, LLC | 7 | $86 |
| AMAG Pharmaceuticals, Inc. | 6 | $80 |
| Rigel Pharmaceuticals, Inc. | 5 | $79 |
| Pfizer | 7 | $76 |
| Incyte Corporation | 5 | $71 |
| Tactile Systems Technology Inc | 2 | $55 |
| Sumitomo Pharma America, Inc. | 1 | $54 |
| Genentech USA, Inc. | 3 | $51 |
| Taiho Oncology, Inc. | 3 | $46 |
| Daiichi Sankyo Inc. | 3 | $40 |
| Biocompatibles, Inc. | 2 | $40 |
| Seagen Inc. | 3 | $37 |
| Agios Pharmaceuticals, Inc. | 3 | $36 |
| Tesaro, Inc. | 2 | $32 |
| Novartis | 1 | $18 |
| Sanofi | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Dendreon Pharmaceuticals LLC | 1 | $13 |
| Secura Bio, Inc. | 1 | $13 |
| Advanced Accelerator Applications | 1 | $12 |
| Gilead | 1 | $12 |
| Dova Pharmaceuticals | 1 | $12 |
| Exelixis Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,479 in reported general payments places this provider in the 55th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 27 | $381,899 |
| JakafiRuxolitinib Phosphate | 20 | $342,378 |
| RevlimidLenalidomide | 21 | $338,728 |
| Lenalidomide | 22 | $311,677 |
| CalquenceAcalabrutinib Maleate | 19 | $291,753 |
| RetevmoSelpercatinib | 12 | $284,012 |
| ImbruvicaIbrutinib | 14 | $229,075 |
| Abiraterone Acetate | 75 | $178,091 |
| XareltoRivaroxaban | 76 | $63,553 |
| EliquisApixaban | 65 | $53,886 |
| Anastrozole | 261 | $4,843 |
| Prochlorperazine Maleate | 91 | $3,247 |
| Oxycodone Hcl | 90 | $1,701 |
| Imatinib Mesylate | 21 | $1,537 |
| Dexamethasone | 65 | $1,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $71 | $342,37820 claims |
| Bristol Myers SquibbRevlimid | $124 | $338,72821 claims |
| AstraZenecaCalquence | $280 | $291,75319 claims |
| Lilly USA, LLCRetevmo, Olanzapine | $86 | $284,23828 claims |
| Johnson & JohnsonXarelto | $245 | $63,55376 claims |
| PfizerEliquis | $76 | $53,88665 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Beaver
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.